NCT04819841: An ongoing trial by Kamau Therapeutics
This trial is ongoing. It must report results 2 years from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04819841 |
|---|---|
| Title | A Phase I/II Study of Nula-cel in Autologous CD34+ Hematopoietic Stem Cells to Convert HbS to HbA for Treating Severe Sickle Cell Disease |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 15, 2021 |
| Completion date | Dec. 31, 2026 |
| Required reporting date | Dec. 31, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |